Merrimack Pharmaceuticals

Merrimack is a fully integrated biopharmaceutical company that views cancer as a complex engineering challenge. Through systems biology, which brings together the fields of biology, computing and engineering, Merrimack aims to decrease uncertainty in drug development and clinical validation, and move discovery efforts beyond trial and error. Such an approach has the potential to make individualized treatment of patients a reality. Merrimack's first commercial product, ONIVYDETM (irinotecan liposome injection), was approved by the U.S. FDA on October 22, 2015. With four additional candidates in clinical studies, several in preclinical development and multiple biomarkers designed to support patient selection, Merrimack is building one of the most robust oncology pipelines in the industry.

Company Growth (employees)
Cambridge, US
Size (employees)
294 (est)-30%
Merrimack Pharmaceuticals was founded in 2000 and is headquartered in Cambridge, US

Key People at Merrimack Pharmaceuticals

Robert J. Mulroy

Robert J. Mulroy

President and Chief Executive Officer, Board of Directors
Ulrik B. Nielsen

Ulrik B. Nielsen

Gary Crocker

Gary Crocker

Peter Laivins

Peter Laivins

Team Member
Edward J. Stewart

Edward J. Stewart

Team Member
William A. Sullivan

William A. Sullivan

Team Member

Merrimack Pharmaceuticals Office Locations

Merrimack Pharmaceuticals has an office in Cambridge
Cambridge, US (HQ)
1 Kendall Square

Merrimack Pharmaceuticals Data and Metrics

Merrimack Pharmaceuticals Financial Metrics

Merrimack Pharmaceuticals's revenue was reported to be $144.3 m in FY, 2016 which is a 62% increase from the previous period.
Numbers are in $, USD

Revenue (FY, 2016)

144.3 m

Revenue growth (FY, 2015 - FY, 2016), %


Gross profit (FY, 2016)

137.4 m

Gross profit margin (FY, 2016), %


Net income (FY, 2016)

(153.5 m)

EBIT (FY, 2016)

(110.1 m)

Market capitalization (26-May-2017)

437 m

Closing share price (26-May-2017)


Cash (31-Dec-2016)

21.5 m
Merrimack Pharmaceuticals's current market capitalization is $437 m.
Numbers are in $, USDFY, 2013FY, 2014FY, 2015FY, 2016


47.8 m102.8 m89.3 m144.3 m

Revenue growth, %


Cost of goods sold

6.9 m

Gross profit

89.2 m137.4 m

Gross profit Margin, %


Operating expense total

218.8 m254.4 m


(120.5 m)(66.3 m)(129.6 m)(110.1 m)

EBIT margin, %


Interest expense

19.2 m43.6 m

Interest income

99 k276 k

Net Income

(130.7 m)(83.6 m)(147.8 m)(153.5 m)
Numbers are in $, USDFY, 2013FY, 2014FY, 2015FY, 2016


65.1 m35.7 m185.6 m21.5 m

Accounts Receivable

5.9 m3.3 m6.5 m17.5 m


5.5 m4.7 m5.5 m3.8 m

Current Assets

166.6 m132.1 m201.4 m57.4 m


13.4 m14.5 m21.9 m15.8 m


3.6 m3.6 m3.6 m3.6 m

Total Assets

192.4 m158.7 m234.9 m81.5 m

Accounts Payable

Current Liabilities

57.7 m111.1 m103.7 m88.2 m

Additional Paid-in Capital

527.8 m552 m617.1 m702.4 m

Retained Earnings

(572.2 m)(655.2 m)(802.2 m)(954.8 m)

Total Equity

(43.5 m)(102.1 m)(183.9 m)

Financial Leverage

-4.4 x-1.6 x-1.3 x
Numbers are in $, USDFY, 2013FY, 2014FY, 2015FY, 2016

Net Income

(130.7 m)(83.6 m)(147.8 m)(153.5 m)

Depreciation and Amortization

2.6 m3.2 m4.3 m6.2 m

Accounts Receivable

3.4 m2.6 m(3.2 m)(11 m)


4 m827 k(850 k)1.9 m

Accounts Payable

Cash From Operating Activities

(95.2 m)(34.8 m)149.9 m(170.2 m)

Purchases of PP&E

(9.9 m)(6 m)(12.8 m)(3.2 m)

Cash From Investing Activities

(27.7 m)(6 m)75.1 m(3.3 m)

Cash From Financing Activities

150.3 m11.4 m180.2 m9.4 m

Interest Paid

3.9 m9.5 m10.1 m23.9 m
Numbers are in $, USDY, 2016


338.7 k

Merrimack Pharmaceuticals Market Value History

Merrimack Pharmaceuticals Median Salaries

Source: 20 public H-1B filings from Merrimack Pharmaceuticals

Merrimack Pharmaceuticals Online and Social Media Presence

Merrimack Pharmaceuticals News and Updates

Merrimack Pharmaceuticals Company Life and Culture

You may also be interested in